S&P 500 Futures
(-0.07%) 5 045.50 points
Dow Jones Futures
(-0.09%) 37 971 points
Nasdaq Futures
(-0.21%) 17 511 points
Oil
(-0.74%) $82.12
Gas
(-0.68%) $1.745
Gold
(-0.22%) $2 392.80
Silver
(-0.42%) $28.26
Platinum
(-1.69%) $938.40
USD/EUR
(-0.12%) $0.938
USD/NOK
(-0.11%) $11.03
USD/GBP
(-0.11%) $0.803
USD/RUB
(-0.67%) $93.27

Realtime updates for Verici Dx plc [VRCI.L]

Exchange: LSE Sector: Healthcare Industry: Diagnostics & Research
Last Updated19 Apr 2024 @ 07:02

3.18% £ 8.25

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 07:02):

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients...

Stats
Today's Volume 10 966.00
Average Volume 368 143
Market Cap 20.02M
EPS £0 ( 2023-10-05 )
Next earnings date ( £0 ) 2024-05-30
Last Dividend £0 ( N/A )
Next Dividend £0 ( N/A )
P/E -1.650
ATR14 £0 (0.00%)

Verici Dx plc Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Verici Dx plc Financials

Annual 2022
Revenue: £0
Gross Profit: £0 (0.00 %)
EPS: £-0.0690
Q2 2023
Revenue: £9 500.00
Gross Profit: £8 000.00 (84.21 %)
EPS: £-0.0155
Q1 2023
Revenue: £9 500.00
Gross Profit: £8 000.00 (84.21 %)
EPS: £-0.0155
Q4 2022
Revenue: £0
Gross Profit: £0 (0.00 %)
EPS: £-0.0174

Financial Reports:

No articles found.

Verici Dx plc

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators